Literature DB >> 28440033

Rigor, reproducibility, and in vitro cerebrospinal fluid assays: The devil in the details.

Olivia A Moody1, Sahil Talwar2, Meagan A Jenkins3, Amanda A Freeman4, Lynn Marie Trotti5, Paul S García1,6,7, Donald Bliwise5, Joseph W Lynch2,8, Brad Cherson9, Eric M Hernandez10, Neil Feldman11, Prabhjyot Saini5, David B Rye1,5, Andrew Jenkins1,7,12.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28440033      PMCID： PMC5639705          DOI： 10.1002/ana.24940

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


× No keyword cloud information.
  18 in total

1.  Endogenous benzodiazepine receptor ligands in idiopathic recurring stupor.

Authors:  J D Rothstein; A Guidotti; P Tinuper; P Cortelli; P Avoni; G Plazzi; E Lugaresi; P Schoch; P Montagna
Journal:  Lancet       Date:  1992-10-24       Impact factor: 79.321

Review 2.  Pharmacology of flumazenil.

Authors:  J G Whitwam; R Amrein
Journal:  Acta Anaesthesiol Scand Suppl       Date:  1995

Review 3.  Intrinsic actions of the benzodiazepine receptor antagonist Ro 15-1788.

Authors:  S E File; S Pellow
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

4.  Dose-dependent effects of flumazenil on cognition, mood, and cardio-respiratory physiology in healthy volunteers.

Authors:  N Neave; C Reid; A B Scholey; J M Thompson; M Moss; G Ayre; K Wesnes; N M Girdler
Journal:  Br Dent J       Date:  2000-12-23       Impact factor: 1.626

5.  Clarithromycin in γ-aminobutyric acid-Related hypersomnolence: A randomized, crossover trial.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Donald L Bliwise; Amanda A Freeman; Andrew Jenkins; David B Rye
Journal:  Ann Neurol       Date:  2015-06-30       Impact factor: 10.422

6.  Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Catherine Koola; Vincent LaBarbera; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

7.  Endogenous positive allosteric modulation of GABA(A) receptors by diazepam binding inhibitor.

Authors:  Catherine A Christian; Anne G Herbert; Rebecca L Holt; Kathy Peng; Kyla D Sherwood; Susanne Pangratz-Fuehrer; Uwe Rudolph; John R Huguenard
Journal:  Neuron       Date:  2013-05-30       Impact factor: 17.173

8.  Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors.

Authors:  David B Rye; Donald L Bliwise; Kathy Parker; Lynn Marie Trotti; Prabhjyot Saini; Jacqueline Fairley; Amanda Freeman; Paul S Garcia; Michael J Owens; James C Ritchie; Andrew Jenkins
Journal:  Sci Transl Med       Date:  2012-11-21       Impact factor: 17.956

9.  Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Amanda A Freeman; Donald L Bliwise; Paul S García; Andrew Jenkins; David B Rye
Journal:  J Psychopharmacol       Date:  2013-12-03       Impact factor: 4.153

10.  Chemical characterization of a family of brain lipids that induce sleep.

Authors:  B F Cravatt; O Prospero-Garcia; G Siuzdak; N B Gilula; S J Henriksen; D L Boger; R A Lerner
Journal:  Science       Date:  1995-06-09       Impact factor: 47.728
View more
  1 in total

1.  De novo variants in GABRA2 and GABRA5 alter receptor function and contribute to early-onset epilepsy.

Authors:  Kameryn M Butler; Olivia A Moody; Elisabeth Schuler; Jason Coryell; John J Alexander; Andrew Jenkins; Andrew Escayg
Journal:  Brain       Date:  2018-08-01       Impact factor: 13.501
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.